BiotechTube
Engineered BioPharmaceuticals

Engineered BioPharmaceuticals

San Diego, United States· Est.
engbiopharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Engineered BioPharmaceuticals, founded in 2014, is a private, pre-revenue biotech company developing advanced drug delivery systems aimed at reducing healthcare costs through improved patient compliance. Its core innovation is the GelRx™ oral delivery technology, designed to fit seamlessly into a patient's lifestyle. The company leverages over 14 years of collective expertise in pharmaceutical engineering and is led by a seasoned executive team with strong backgrounds in medical devices and pharmaceutical development. Its initial focus is on advancing its first prescription pharmaceutical product based on this platform.

Drug Delivery

Technology Platform

GelRx™, a proprietary technology platform designed for the easy oral delivery of active pharmaceutical ingredients (APIs), likely involving gel-based or advanced solid dosage formulations.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

The global push for cost-effective healthcare and improved medication adherence creates a significant market for user-friendly drug delivery platforms.
Oral delivery remains the preferred route, offering a vast addressable market for a successful technology that can enhance compliance and drug performance.

Risk Factors

The company is at an early, pre-revenue stage with an unproven clinical platform, facing high technical and development risks.
Its progress is fully dependent on securing additional funding in a competitive capital environment, and it operates in a crowded drug delivery sector with established players.

Competitive Landscape

The advanced drug delivery market is highly competitive, featuring large CDMOs (Catalent, Lonza), specialty pharma companies, and numerous biotech startups. Success requires demonstrating clear differentiation in ease of use, manufacturing scalability, and clinical benefit over existing oral dosage forms.

More companies in United States →